Table 2.
Allelic and genotypic frequencies and association analysis – rs12979860.
| Controls (n = 190) | Patients (total) (n = 227) | Comparison | OR (CI 95%) | p | |
|---|---|---|---|---|---|
| Genotype | |||||
| CC | 90 (47.4%) | 66 (29.1%) | – | – | – |
| CT | 83 (43.7%) | 117 (51.5%) | TT+CT vs. CC | 2.195 (1.437–3.357) | <0.001* |
| TT | 17 (8.9%) | 44 (19.4%) | TT vs. CT+CC | 2.447 (1.300–4.648) | 0.005* |
| p | – | <0.001A* | – | – | – |
| Allele | |||||
| C | 263 (69.2%) | 249 (54.9%) | – | – | – |
| T | 117 (30.8%) | 205 (45.1%) | T vs. C | 1.851 (1.377–2.488) | <0.001* |
| p | – | <0.001B* | – | – | – |
| Controls (n = 190) | HCV patients (n = 175) | Comparison | OR (CI 95%) | p | |
| Genotype | |||||
| CC | 90 (47.4%) | 54 (30.9%) | – | – | – |
| CT | 83 (43.7%) | 84 (48.0%) | TT+CT vs. CC | 2.017 (1.284–3.170) | 0.002* |
| TT | 17 (8.9%) | 37 (21.1%) | TT vs. CT+CC | 2.728 (1.417–5.296) | 0.002* |
| p | – | <0.001C* | – | – | – |
| Allele | |||||
| C | 263 (69.2%) | 192 (54.9%) | – | – | – |
| T | 117 (30.8%) | 158 (45.1%) | T vs. C | 1.850 (1.351–2.534) | <0.001* |
| p | – | <0.001D* | – | – | – |
| Controls (n = 190) | HCV/HIV-1 patients (n = 52) | Comparison | OR (CI 95%) | p | |
| Genotype | |||||
| CC | 90 (47.4%) | 12 (23.5%) | – | – | – |
| CT | 83 (43.7%) | 33 (62.8%) | TT+CT vs. CC | 3.000 (1.413–6.469) | 0.003* |
| TT | 17 (8.9%) | 7 (13.7%) | TT vs. CT+CC | 1.583 (0.556–4.374) | 0.482 |
| p | – | 0.007E* | – | – | – |
| Allele | |||||
| C | 263 (69.2%) | 57 (54.8%) | – | – | - |
| T | 117 (30.8%) | 47 (45.2%) | T vs. C | 1.854 (1.162–2.957) | 0.009* |
| p | – | 0.009F* | – | – | – |
| HCV patients (n = 175) | HCV/HIV-1 patients (n = 52) | Comparison | OR (CI 95%) | p | |
| Genotype | |||||
| CC | 54 (30.9%) | 12 (23.5%) | – | – | – |
| CT | 84 (48.0%) | 33 (62.8%) | TT+CT vs. CC | 1.488 (0.688–3.263) | 0.363 |
| TT | 37 (21.1%) | 7 (13.7%) | TT vs. CT+CC | 0.580 (0.219–1.479) | 0.303 |
| p | – | 1.000G | – | – | – |
| Allele | |||||
| C | 192 (54.9%) | 57 (54.8%) | – | – | – |
| T | 158 (45.1%) | 47 (45.2%) | T vs. C | 1.002 (0.630–1.592) | 1.000 |
| p | – | 1.000H | – | – | – |
A,BControls vs. Patients (total); C,DControls vs. HCV Patients; E,FControls vs. HCV/HIV-1 Patients; G,HHCV Patients vs; HCV/HIV-1 Patients; OR, Odds ratio; CI, Confidence intervals. *Statistical significance.